Medium-dose ICS-containing FDCs reduce all-cause mortality in COPD patients: an in-depth analysis of dual and triple therapies.

Luigino CalzettaBeatrice Ludovica RitondoMaria Gabriella MateraAlfredo ChettaRogliani Paola

Published in: Expert review of respiratory medicine (2021)

MD ICS/LABA/LAMA and MD ICS/LABA FDCs were effective in reducing on-treatment all-cause of death, with MD ICS/LABA/LAMA FDC being effective also against adjudicated cardiovascular mortality. The protection against mortality was related with the level of ICS dose in the FDCs.

Keyphrases

molecular dynamics
end stage renal disease
cardiovascular events

ejection fraction
newly diagnosed
chronic kidney disease

chronic obstructive pulmonary disease
muscular dystrophy

prognostic factors
lung function